<?xml version="1.0" encoding="UTF-8"?>
<ref id="B12-viruses-12-00177">
 <label>12.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="editor">
   <name>
    <surname>Vogelzang</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Taub</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Shin</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Costanzi</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Pass</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Gutheil</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Georgiadis</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>McAndrew</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Kelly</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Chun</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (pts) with unresectable malignant mesothelioma (UMM): Analysis of survival</article-title>
  <source>Proc. Am. Soc. Clin. Oncol.</source>
  <year>2000</year>
  <volume>19</volume>
  <fpage>577a</fpage>
 </element-citation>
</ref>
